pillbase.ru

Praluent

Active substance: alirocumab

INJECTION, SOLUTION · ALIROCUMAB 150 mg/mL

United StatesActive

Marketing holder: Regeneron Pharmaceuticals, Inc.

Verified 2026-10-09 · openFDA NDC

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
RU 2
  • Пралуэнт
    раствор для подкожного введения, 150 мг, 1 мл (original in Russian, GRLS)
    ЛП-№(000321)-(РГ-RU)
    Санофи Винтроп Индустрия
  • Пралуэнт
    раствор для подкожного введения, 150 мг/мл, 1 мл (original in Russian, GRLS)
    ЛП-004078
    АО "Санофи-авентис груп"
EU 1
  • Praluent
    alirocumab
    EMEA/H/C/003882
    Sanofi Winthrop Industrie
Import and control

Control by country

  • Russiaprescription only

    Source: GRLS (Russian state register) · record 01a120c3-357c-774d-87a5-cff914d8cf28,01a120c5-1ce6-701d-a310-7b23bd62e7b6;count=2 · valid from 2026-10-09 · verified 2026-10-09

  • United Statesprescription only

    Source: openFDA NDC · record 01a1208d-4c70-753b-a902-17800c28751d,01a12091-f06d-78b7-9d28-8544f4674b87,01a12098-ed2d-7774-9b81-ba22e4f20420,01a1209d-b172-78e4-917e-82f4e0722aa6;count=4 · valid from 2026-10-09 · verified 2026-10-09

More on control status
Registration
Registration number
61755-021
Registration status
Active
Dispensing
Prescription only
Route
SUBCUTANEOUS
Sources
  • product · openFDA NDC · 61755-021 · Verified 2026-10-09 · open in source
  • registration_status · openFDA NDC · 61755-021 · Verified 2026-10-09 · open in source
  • ingredients.0 · openFDA NDC · 61755-021 · Verified 2026-10-09 · open in source